Retain the Sanofi turbo calls | Photo credits: Sanofi Pasteur РAlexis Chezi̬re
The latest figures released by Sanofi have been encouraging. The pharmaceutical company ‘s earnings per share climbed 19% (constant) in the third quarter, well above expectations. The growth objective for 2021 has thus been raised from + 12% to + 14%. The pharmaceutical group should record continued dynamic growth in 2022, driven in particular by the performance of Dupixent.
We therefore advise you to keep the Sanofi turbo calls of code 00D5B, who are always losers, but who could benefit from the defensive nature of the company in the event of a soft spot in the markets, the share being also always discounted compared to the comparables of the sector. The desacrivating barrier is 19% away from the current level of the action.
Rating range: 1.81-1.82.